Clicky

Werewolf Therapeutics, Inc.(HOWL)

Description: Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It offers PREDATOR, a platform of protein engineering technology to design and engineer the future of immuno-oncology biotherapeutics for patients. The company's lead product candidates include WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. It also develops WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.


Keywords: Biotechnology Cancer Biopharmaceutical Life Sciences Health Sciences Solid Tumors Treatment Of Cancer Cancer Immunotherapy Lymphoma Hematologic Malignancies Advanced Solid Tumors Metastatic Solid Tumors

Home Page: werewolftx.com

HOWL Technical Analysis

1030 Massachusetts Avenue
Cambridge, MA 02138
United States
Phone: 617 952 0555


Officers

Name Title
Dr. Daniel J. Hicklin Ph.D. Founder, CEO, Pres, Sec. & Director
Mr. Timothy W. Trost CPA CFO, Treasurer & Assistant Sec.
Dr. Chulani Karunatilake Ph.D. Chief Technology Officer
Dr. Reid Leonard Ph.D. Chief Operating Officer
Dr. Cynthia Seidel-Dugan Ph.D. Chief Scientific Officer
Dr. Randi Isaacs M.D. Chief Medical Officer
Ms. Ellen A. Lubman M.B.A. Chief Bus. Officer

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0.4333
Price-to-Book MRQ: 0.4203
Price-to-Sales TTM: 6.6088
IPO Date: 2021-04-30
Fiscal Year End: December
Full Time Employees: 48
Back to stocks